Publication:
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study

Simple item page
dc.contributor.authorMonge Corella, Susana
dc.contributor.authorHumphreys, James
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorBraeye, Toon
dc.contributor.authorVan Evercooren, Izaak
dc.contributor.authorHolm Hansen, Christian
dc.contributor.authorEmborg, Hanne-Dorthe
dc.contributor.authorSacco, Chiara
dc.contributor.authorMateo-Urdiales, Alberto
dc.contributor.authorCastilla, Jesús
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorde Gier, Brechje
dc.contributor.authorHahné, Susan
dc.contributor.authorMeijerink, Hinta
dc.contributor.authorKristoffersen, Anja Bråthen
dc.contributor.authorMachado, Ausenda
dc.contributor.authorSoares, Patricia
dc.contributor.authorNardone, Anthony
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKissling, Esther
dc.contributor.authorNunes, Baltazar
dc.contributor.authorVEBIS-EHR Working Group
dc.contributor.funderFundação para a Ciência e Tecnologia (Portugal)
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC)
dc.date.accessioned2024-05-13T08:22:10Z
dc.date.available2024-05-13T08:22:10Z
dc.date.issued2024-04
dc.description.abstractUsing a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipAll the public health organisations involved received funding from the European Centre for Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/018 ‘Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure and outcome using health registries’ (RS/2022/DTS/24104). In Portugal, this work was also supported by FCT – Fundação para a Ciência e Tecnologia, I.P. by project reference CEECINST/00049/2021/CP2817/CT0001 and DOI identifier 10.54499/CEECINST/00049/2021/CP2817/CT0001es_ES
dc.format.number4es_ES
dc.format.pagee13292es_ES
dc.format.volume18es_ES
dc.identifier.citationInfluenza Other Respir Viruses. 2024 Apr;18(4):e13292.es_ES
dc.identifier.doi10.1111/irv.13292es_ES
dc.identifier.e-issn1750-2659es_ES
dc.identifier.journalInfluenza and other respiratory viruseses_ES
dc.identifier.pubmedID38654485es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19372
dc.language.isoenges_ES
dc.publisherWiley
dc.relation.publisherversionhttps://doi.org/10.1111/irv.13292es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCohort designes_ES
dc.subjectCOVID-19es_ES
dc.subjectElectronic health recordses_ES
dc.subjectHospitalisationes_ES
dc.subjectMulticountry studyes_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectVaccine effectivenesses_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshCOVID-19 Vaccineses_ES
dc.subject.meshEuropean Uniones_ES
dc.subject.meshHospitalizationes_ES
dc.subject.meshSARS-CoV-2es_ES
dc.subject.meshVaccine Efficacyes_ES
dc.subject.meshHumanses_ES
dc.subject.meshAgedes_ES
dc.subject.meshMalees_ES
dc.titleEffectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Studyes_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationa0bb4f4f-11f0-487e-bf93-0b13f90057cc
relation.isAuthorOfPublication7ac13a7f-3d30-4846-8b51-b7505c7df45c
relation.isAuthorOfPublication.latestForDiscoverya0bb4f4f-11f0-487e-bf93-0b13f90057cc
relation.isFunderOfPublication25f151af-8d71-4e41-b920-ca8474d267b7
relation.isFunderOfPublication78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isFunderOfPublication.latestForDiscovery25f151af-8d71-4e41-b920-ca8474d267b7
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
EffectivenessXBB15MonovalentCOVID-19Vaccines_2024.pdf
Size:
1.39 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Centro Nacional de Epidemiología (CNE)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)